Vanguard Group Inc. Sells 112,308 Shares of Astrana Health, Inc. $ASTH

Vanguard Group Inc. reduced its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 2.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,721,076 shares of the company’s stock after selling 112,308 shares during the quarter. Vanguard Group Inc. owned 8.42% of Astrana Health worth $133,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. SteelPeak Wealth LLC raised its position in Astrana Health by 7.8% in the 3rd quarter. SteelPeak Wealth LLC now owns 579,937 shares of the company’s stock worth $16,441,000 after buying an additional 41,761 shares during the last quarter. Diamond Hill Capital Management Inc. raised its holdings in shares of Astrana Health by 33.0% during the third quarter. Diamond Hill Capital Management Inc. now owns 361,264 shares of the company’s stock valued at $10,242,000 after purchasing an additional 89,733 shares during the last quarter. Royal Bank of Canada lifted its position in Astrana Health by 6.5% during the first quarter. Royal Bank of Canada now owns 278,619 shares of the company’s stock valued at $8,640,000 after purchasing an additional 17,028 shares during the period. Principal Financial Group Inc. boosted its holdings in Astrana Health by 0.3% in the third quarter. Principal Financial Group Inc. now owns 222,985 shares of the company’s stock worth $6,322,000 after purchasing an additional 611 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB grew its position in Astrana Health by 26.7% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock worth $4,727,000 after purchasing an additional 40,000 shares during the period. 52.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. TD Cowen lowered their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Needham & Company LLC assumed coverage on Astrana Health in a research report on Friday, December 12th. They issued a “buy” rating and a $28.00 target price on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrana Health in a research report on Tuesday, November 25th. Barclays dropped their price objective on shares of Astrana Health from $36.00 to $26.00 and set an “equal weight” rating on the stock in a report on Monday, November 24th. Finally, Zacks Research cut shares of Astrana Health from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $35.33.

Astrana Health Trading Down 6.9%

ASTH stock opened at $24.51 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.40 and a quick ratio of 1.40. Astrana Health, Inc. has a 1-year low of $18.08 and a 1-year high of $34.80. The business has a 50 day simple moving average of $23.56 and a two-hundred day simple moving average of $26.24. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of 53.28, a PEG ratio of 0.78 and a beta of 0.91.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Monday, March 2nd. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.15 by $0.39. Astrana Health had a net margin of 0.71% and a return on equity of 5.63%. The firm had revenue of $950.53 million for the quarter, compared to the consensus estimate of $930.46 million. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. The company’s quarterly revenue was up 42.9% compared to the same quarter last year. Research analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.